Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia

European Neuropsychopharmacology

Volumn 22, Issue 12, 2012, Pages 902-910

  Balla, Andrea ^a   Schneider, Samantha ^a   Sershen, Henry ^a,b   Javitt, Daniel C ^a,c  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Dopamine; Glycine transport inhibitor; NMDA; Prefrontal cortex; Schizophrenia; Striatum

Indexed keywords

CYCLOSERINE; DOPAMINE; NEUROLEPTIC AGENT; ORG 29335; R 231857; R 231860; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; DRUG EFFICACY; IN VIVO STUDY; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; FRONTAL LOBE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME;

EID: 84870717591     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.03.006     Document Type: Article

References (62)

1. Aalto S., Ihalainen J., Hirvonen J., Kajander J., Scheinin H., Tanila H., Nagren K., Vilkman H., Gustafsson L.L., Syvalahti E., Hietala J. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl.) 2005, 182:375-383.
2. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 1998, 18:5545-5554.
3. Alberati D., Borroni E., Moreau J., Hainzl D., Pinnard E., Wettstein J.G. Partial occupancy of the glycine transporter type 1 in rat by RG1678 leads to efficacy in models relevant to schizophrenia. Schizophr. Bull. 2011, 37(Suppl. 1):286.
4. Balla A., Hashim A., Burch S., Javitt D.C., Lajtha A., Sershen H. Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. Neurochem. Res. 2001, 26:1001-1006.
5. Balla A., Koneru R., Smiley J., Sershen H., Javitt D.C. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 2001, 25:157-164.
6. Balla A., Sershen H., Serra M., Koneru R., Javitt D.C. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropsychopharmacology 2003, 28:34-44.
7. Bergeron R., Meyer T.M., Coyle J.T., Greene R.W. Modulation of N-methyl-d-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. U S A 1998, 95:15730-15734.
8. Black M.D., Varty G.B., Arad M., Barak S., De Levie A., Boulay D., Pichat P., Griebel G., Weiner I. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl.) 2009, 202:385-396.
9. Boulay D., Bergis O., Avenet P., Griebel G. The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 2010, 35:416-427.
10. Bowie C.R., Reichenberg A., McClure M.M., Leung W.L., Harvey P.D. Age-associated differences in cognitive performance in older community dwelling schizophrenia patients: differential sensitivity of clinical neuropsychological and experimental information processing tests. Schizophr. Res. 2008, 106:50-58.
11. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 2007, 164:1593-1602.
12. Carlsson M.L., Engberg G., Carlsson A. Effects of d-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice. J. Neural Transm. Gen. Sect. 1994, 95:223-233.
13. Chen L., Muhlhauser M., Yang C.R. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J. Neurophysiol. 2003, 89:691-703.
14. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 1996, 3:241-253.
15. D'Souza D.C., Charney D., Krystal J. Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev. 1995, 1:227-260.
16. D'Souza D.C., Singh N., Elander J., Carbuto M., Pittman B., de Haes J.U., Sjogren M., Peeters P., Ranganathan M., Schipper J. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology 2012, 37:1036-1046.
17. Depoortere R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., Poncelet M., Heaulme M., Santucci V., Decobert M., Cudennec A., Voltz C., Boulay D., Terranova J.P., Stemmelin J., Roger P., Marabout B., Sevrin M., Vige X., Biton B., Steinberg R., Francon D., Alonso R., Avenet P., Oury-Donat F., Perrault G., Griebel G., George P., Soubrie P., Scatton B. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005, 30:1963-1985.
18. Fusar-Poli P., Howes O.D., Allen P., Broome M., Valli I., Asselin M.C., Grasby P.M., McGuire P.K. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch. Gen. Psychiatry 2010, 67:683-691.
19. Gaisler-Salomon I., Diamant L., Rubin C., Weiner I. Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. Psychopharmacology (Berl.) 2008, 196:255-267.
20. Harsing L. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Phamacol. Biochem. Behav. 2003, 74:811-825.
21. Heresco-Levy U., Javitt D.C. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr. Res. 2004, 66:89-96.
22. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35:549-562.
23. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Valli I., Tabraham P., Bramon-Bosch E., Valmaggia L., Johns L., Broome M., McGuire P.K., Grasby P.M. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66:13-20.
24. Javitt D.C. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr. Opinion Drug Discovery Dev 2009, 12:468-478.
25. Javitt D.C., Balla A., Burch S., Suckow R., Xie S., Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-d-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 2004, 29:300-307.
26. Javitt D.C., Balla A., Sershen H., Lajtha A. A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol. Psychiatry 1999, 45:668-679.
27. Javitt D.C., Frusciante M. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. Psychopharmacology (Berl.) 1997, 129:96-98.
28. Javitt D.C., Schoepp D., Kalivas P.W., Volkow N.D., Zarate C., Merchant K., Bear M.F., Umbricht D., Hajos M., Potter W.Z., Lee C.M. Translating glutamate: from pathophysiology to treatment. Sci. Transl. Med. 2011, 3. (102mr102).
29. Javitt D.C., Sershen H., Hashim A., Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 1997, 17:202-204.
30. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
31. Kantrowitz J.T., Javitt D.C. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res. Bull. 2010, 83:108-121.
32. Kargieman L., Santana N., Mengod G., Celada P., Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc. Natl. Acad. Sci. U S A 2007, 104:14843-14848.
33. Kegeles L.S., Abi-Dargham A., Frankle W.G., Gil R., Cooper T.B., Slifstein M., Hwang D.R., Huang Y., Haber S.N., Laruelle M. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch. Gen. Psychiatry 2010, 67:231-239.
34. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., Cooper T.B., Carlsson A., Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 2000, 48:627-640.
35. Kellendonk C., Simpson E.H., Kandel E.R. Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci. 2009, 32:347-358.
36. Kristiansen L.V., Huerta I., Beneyto M., Meador-Woodruff J.H. NMDA receptors and schizophrenia. Curr. Opin. Pharmacol. 2007, 7:48-55.
37. Krystal J.H., Anand A., Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch. Gen. Psychiatry 2002, 59:663-664.
38. Lane H.Y., Liu Y.C., Huang C.L., Chang Y.C., Liau C.H., Perng C.H., Tsai G.E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol. Psychiatry 2008, 63:9-12.
39. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 1999, 46:56-72.
40. Liem-Moolenaar M., Zoethout R.W., de Boer P., Schmidt M., de Kam M.L., Cohen A.F., Franson K.L., van Gerven J.M. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. J. Psychopharmacol. 2010, 24:1681-1687.
41. Linn G.S., O'Keeffe R.T., Lifshitz K., Schroeder C., Javitt D.C. Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. Psychopharmacology (Berl.) 2007, 192:27-38.
42. Lipina T., Labrie V., Weiner I., Roder J. Modulators of the glycine site on NMDA receptors, d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl.) 2005, 179:54-67.
43. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
44. Martina M., Gorfinkel Y., Halman S., Lowe J.A., Periyalwar P., Schmidt C.J., Bergeron R. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J. Physiol. 2004, 557:489-500.
45. Miyamoto Y., Yamada K., Noda Y., Mori H., Mishina M., Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J. Neurosci. 2001, 21:750-757.
46. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15.
47. Morita Y., Ujike H., Tanaka Y., Kishimoto M., Okahisa Y., Kotaka T., Harano M., Inada T., Komiyama T., Hori T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N., Kuroda S. The glycine transporter 1 gene (GLYT1) is associated with methamphetamine-use disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:54-58.
48. Nagy K., Marko B., Zsilla G., Matyus P., Pallagi K., Szabo G., Juranyi Z., Barkoczy J., Levay G., Harsing L.G. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Neurochem. Res. 2010, 35:2096-2106.
49. Papp A., Juranyi Z., Nagymajtenyi L., Matyus P., Harsing L.G. The synaptic and nonsynaptic glycine transporter type-1 inhibitors Org-24461 and NFPS alter single neuron firing rate in the rat dorsal raphe nucleus. Further evidence for a glutamatergic-serotonergic interaction and its role in antipsychotic action. Neurochem. Int. 2008, 52:130-134.
50. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, fourth ed. Academic Press 1998.
51. Pinard E., Alanine A., Alberati D., Bender M., Borroni E., Bourdeaux P., Brom V., Burner S., Fischer H., Hainzl D., Halm R., Hauser N., Jolidon S., Lengyel J., Marty H.P., Meyer T., Moreau J.L., Mory R., Narquizian R., Nettekoven M., Norcross R.D., Puellmann B., Schmid P., Schmitt S., Stalder H., Wermuth R., Wettstein J.G., Zimmerli D. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfon yl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J. Med. Chem. 2010, 53:4603-4614.
52. Roberts B.M., Shaffer C.L., Seymour P.A., Schmidt C.J., Williams G.V., Castner S.A. Glycine transporter inhibition reverses ketamine-induced working memory deficits. Neuroreport 2010, 21:390-394.
53. Sershen H., Balla A., Aspromonte J.M., Xie S., Cooper T.B., Javitt D.C. Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: implications in NMDA/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function. Neurochem. Int. 2008, 52:119-129.
54. Singer P., Feldon J., Yee B.K. The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice. Psychopharmacology (Berl.) 2009, 202:371-384.
55. Singer P., Feldon J., Yee B.K. Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour. Eur. Neuropsychopharmacol. 2009, 19:571-580.
56. Singh S.P., Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011, 25:859-885.
57. Tsai G.E., Lin P.Y. Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 2010, 16:522-537.
58. Tsukada H., Nishiyama S., Fukumoto D., Sato K., Kakiuchi T., Domino E.F. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 2005, 30:1861-1869.
59. Umbricht D., Yoo K., Youssef E., Dorflinger E., Martin-Facklam M., Bausch A., Arrowsmith R., Alberati D., Marder S.R., Santarelli L. Glycine Transporter Type 1 (GLYT1) Inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Neuropsychopharmacology 2010, 35:s320-s321.
60. Vanneste S., De Ridder D. Bifrontal transcranial direct current stimulation modulates tinnitus intensity and tinnitus-distress-related brain activity. Eur. J. Neurosci. 2011, 34:605-614.
61. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 1996, 16:373-379.
62. Zaehle T., Beretta M., Jancke L., Herrmann C.S., Sandmann P. Excitability changes induced in the human auditory cortex by transcranial direct current stimulation: direct electrophysiological evidence. Exp. Brain Res. 2011, 215:135-140.